Report Detail
Cardiac Resynchronisation Therapy (CRT) - Medical Devices Pipeline Assessment, 2019
- RnM3864398 |
- 10 January, 2020 |
- Global |
- 90 Pages |
- GlobalData |
- Medical Devices & Consumables
Cardiac Resynchronisation Therapy (CRT) - Medical Devices Pipeline Assessment, 2019
Summary
GlobalData's Medical Devices sector report, “Cardiac Resynchronisation Therapy (CRT) - Medical Devices Pipeline Assessment, 2019" provides an overview of Cardiac Resynchronisation Therapy (CRT) currently in pipeline stage.
The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Cardiac Resynchronisation Therapy (CRT) pipeline products.
This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.
Scope
- Extensive coverage of the Cardiac Resynchronisation Therapy (CRT) under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of Cardiac Resynchronisation Therapy (CRT) and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment / industry
Reasons to buy
The report enables you to -
- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of Cardiac Resynchronisation Therapy (CRT) under development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the product’s current stage of development, territory and estimated launch date
Table of Contents
- 1.1 List of Tables 4
- 1.2 List of Figures 5
2 Introduction 6
- 2.1 Cardiac Resynchronisation Therapy (CRT) Overview 6
3 Products under Development 7
- 3.1 Cardiac Resynchronisation Therapy (CRT) - Pipeline Products by Stage of Development 7
- 3.2 Cardiac Resynchronisation Therapy (CRT) - Pipeline Products by Segment 8
- 3.3 Cardiac Resynchronisation Therapy (CRT) - Pipeline Products by Territory 9
- 3.4 Cardiac Resynchronisation Therapy (CRT) - Pipeline Products by Regulatory Path 10
- 3.5 Cardiac Resynchronisation Therapy (CRT) - Pipeline Products by Estimated Approval Date 11
- 3.6 Cardiac Resynchronisation Therapy (CRT) - Ongoing Clinical Trials 12
4 Cardiac Resynchronisation Therapy (CRT) - Pipeline Products under Development by Companies 13
- 4.1 Cardiac Resynchronisation Therapy (CRT) Companies - Pipeline Products by Stage of Development 13
- 4.2 Cardiac Resynchronisation Therapy (CRT) - Pipeline Products by Stage of Development 14
5 Cardiac Resynchronisation Therapy (CRT) Companies and Product Overview 15
- 5.1 Boston Scientific Corp Company Overview 15
- 5.1.1 Boston Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview 15
- 5.2 DHS Medical Company Overview 20
- 5.2.1 DHS Medical Pipeline Products & Ongoing Clinical Trials Overview 20
- 5.3 EBR Systems Inc Company Overview 22
- 5.3.1 EBR Systems Inc Pipeline Products & Ongoing Clinical Trials Overview 22
- 5.4 IRadimed Corp Company Overview 26
- 5.4.1 IRadimed Corp Pipeline Products & Ongoing Clinical Trials Overview 26
- 5.5 Johns Hopkins University Company Overview 27
- 5.5.1 Johns Hopkins University Pipeline Products & Ongoing Clinical Trials Overview 27
- 5.6 Mayo Clinic Company Overview 28
- 5.6.1 Mayo Clinic Pipeline Products & Ongoing Clinical Trials Overview 28
- 5.7 Medtronic plc Company Overview 29
- 5.7.1 Medtronic plc Pipeline Products & Ongoing Clinical Trials Overview 29
- 5.8 MicroPort CRM Company Overview 31
- 5.8.1 MicroPort CRM Pipeline Products & Ongoing Clinical Trials Overview 31
- 5.9 NewPace Ltd Company Overview 33
- 5.9.1 NewPace Ltd Pipeline Products & Ongoing Clinical Trials Overview 33
- 5.10 Odem Medical Ltd Company Overview 34
- 5.10.1 Odem Medical Ltd Pipeline Products & Ongoing Clinical Trials Overview 34
6 Cardiac Resynchronisation Therapy (CRT)- Recent Developments 35
- 6.1 Nov 19, 2019: Medtronic reports second quarter financial results for the year 2019 35
- 6.2 Nov 14, 2019: Medtronic highlights leadership in inclusion, diversity, and equity in 2019 integrated performance report 37
- 6.3 Oct 30, 2019: LivaNova reports third quarter 2019 results 38
- 6.4 Oct 23, 2019: Boston Scientific announces results for third quarter 2019 39
- 6.5 Oct 21, 2019: Sean Salmon named executive vice president and group president of Medtronic Diabetes 41
7 Appendix 87
- 7.1 Methodology 87
- 7.2 About GlobalData 90
- 7.3 Contact Us 90
Summary:
Get latest Market Research Reports on Cardiac Resynchronisation Therapy (CRT). Industry analysis & Market Report on Cardiac Resynchronisation Therapy (CRT) is a syndicated market report, published as Cardiac Resynchronisation Therapy (CRT) - Medical Devices Pipeline Assessment, 2019. It is complete Research Study and Industry Analysis of Cardiac Resynchronisation Therapy (CRT) market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
